Online citations, reference lists, and bibliographies.
← Back to Search

Targeting Of Tumor Endothelium By RGD-grafted PLGA-nanoparticles Loaded With Paclitaxel.

F. Danhier, B. Vroman, N. Lecouturier, N. Crokart, V. Pourcelle, H. Freichels, C. Jérôme, J. Marchand-Brynaert, O. Féron, V. Préat
Published 2009 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Paclitaxel (PTX)-loaded PEGylated PLGA-based nanoparticles (NP) have been previously described as more effective in vitro and in vivo than taxol. The aim of this study was to test the hypothesis that our PEGylated PLGA-based nanoparticles grafted with the RGD peptide or RGD-peptidomimetic (RGDp) would target the tumor endothelium and would further enhance the anti-tumor efficacy of PTX. The ligands were grafted on the PEG chain of PCL-b-PEG included in the nanoparticles. We observed in vitro that RGD-grafted nanoparticles were more associated to human umbilical vein endothelial cells (HUVEC) by binding to alpha(v)beta(3) integrin than non-targeted nanoparticles. Doxorubicin was also used to confirm the findings observed for PTX. In vivo, we demonstrated the targeting of RGD and RGDp-grafted nanoparticles to tumor vessels as well as the effective retardation of TLT tumor growth and prolonged survival times of mice treated by PTX-loaded RGD-nanoparticles when compared to non-targeted nanoparticles. Hence, the targeting of anti-cancer drug to tumor endothelium by RGD-labeled NP is a promising approach.
This paper references
10.1038/nm0902-918
A reevaluation of integrins as regulators of angiogenesis
R. Hynes (2002)
10.1002/cbic.200800045
Rational Design of Highly Active and Selective Ligands for the α5β1 Integrin Receptor
D. Heckmann (2008)
10.1016/J.BIOMATERIALS.2004.11.042
Cell adhesive PET membranes by surface grafting of RGD peptidomimetics.
S. Biltresse (2005)
10.1016/j.addr.2008.02.008
Recent advances in the synthesis of aliphatic polyesters by ring-opening polymerization.
C. Jérôme (2008)
Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect.
Ju-Ock Nam (2003)
PDGF - regulated rab - 4 dependent recycling of alpha v beta 3 integrin from early endosomes is necessary for cell adhesion and spearing
S. Bauer Breunig (2001)
10.1016/j.jconrel.2008.09.086
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
F. Danhier (2009)
10.1016/J.BMC.2004.07.055
Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests.
S. Biltresse (2004)
10.1021/bm900027r
Light induced functionalization of PCL-PEG block copolymers for the covalent immobilization of biomolecules.
V. Pourcelle (2009)
10.1200/JCO.1990.8.7.1263
Hypersensitivity reactions from taxol.
R. Weiss (1990)
10.1073/pnas.0803728105
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
E. Murphy (2008)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1016/J.DRUP.2005.10.002
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
K. Temming (2005)
The role of integrin alpha5beta1 in the regulation of corneal neovascularization.
P. Muether (2007)
10.1074/JBC.M300358200
Identification of the αvβ3 Integrin-interacting Motif of βig-h3 and Its Anti-angiogenic Effect*
Ju-Ock Nam (2003)
10.1039/B517706E
Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.
E. Garanger (2006)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1016/J.EJPB.2007.06.010
Polymers and nanoparticles: intelligent tools for intracellular targeting?
M. Breunig (2008)
10.1016/S0378-5173(01)00986-3
Paclitaxel and its formulations.
A. K. Singla (2002)
10.1016/S0142-9612(03)00343-0
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond.
U. Hersel (2003)
Non peptidic alphavbeta3 antagonists: recent developments.
B. Cacciari (2005)
Paclitaxel-loaded PLGA nanoparticles: preparation
C. Fonseca (2002)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1016/J.JCONREL.2003.12.020
Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery.
J. Park (2004)
10.1038/277665a0
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
10.1038/nrc724
Specialization of tumour vasculature
E. Ruoslahti (2002)
10.1016/S0360-3016(02)04505-4
Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses.
B. Jordan (2003)
10.1016/j.ejpb.2009.04.009
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination.
V. Fiévez (2009)
10.1038/35025220
Angiogenesis in cancer and other diseases
P. Carmeliet (2000)
10.1016/S0168-3659(00)00280-7
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates.
H. Yoo (2000)
10.1016/J.EXER.2007.06.004
The role of integrin α5β1 in the regulation of corneal neovascularization
P. Muether (2007)
10.1038/nrd2614
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
10.1016/j.urolonc.2007.03.015
Nanoparticles for drug delivery in cancer treatment.
B. Haley (2008)
Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells.
R. Swerlick (1992)
10.1021/BM700841Y
PCL-PEG-based nanoparticles grafted with GRGDS peptide: preparation and surface analysis by XPS.
V. Pourcelle (2007)
10.2174/138161206777947740
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
A. Meyer (2006)
10.1126/SCIENCE.7512751
Requirement of vascular integrin alpha v beta 3 for angiogenesis.
P. Brooks (1994)
10.1126/SCIENCE.279.5349.377
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
W. Arap (1998)
10.1515/9783111413426-013
L
Il Liceo (1824)
10.1016/J.JCONREL.2007.04.021
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination.
M. Garinot (2007)
10.1016/S0168-3659(02)00212-2
Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.
Cristina Fonseca (2002)
10.1007/3-540-26367-5_1
A
A. Spring (2005)
10.1182/BLOOD.V88.2.667.BLOODJOURNAL882667
Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.
A. Griffioen (1996)
10.2174/0929867053363522
Non Peptidic αvβ3 Antagonists: Recent Developments
B. Cacciari (2005)
10.1016/J.CHROMA.2004.11.093
6-Oxy-(N-succinimidyl acetate)-9-(2'-methoxycarbonyl)fluorescein as a new fluorescent labeling reagent for aliphatic amines in environmental and food samples using high-performance liquid chromatography.
L. Cao (2005)
10.1166/JNN.2006.476
Human vascular endothelial cells in primary cell culture for the evaluation of nanoparticle bioadhesion.
C. Löhbach (2006)
10.1016/J.JCONREL.2006.12.023
Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium.
A. des Rieux (2007)
10.1016/J.JCONREL.2005.03.030
Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
X. Xiong (2005)
10.1016/J.JCONREL.2004.09.008
In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide).
Miechel L T Zweers (2004)
10.1016/S0960-9822(01)00442-0
PDGF-regulated rab4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading
M. Roberts (2001)
10.1016/S0168-3659(02)00206-7
Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.
A. J. Schraa (2002)
Tumour-Target
T. Lammers (2008)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo.
H. Hall (2004)
10.1002/JBM.A.31615
Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery.
Z. Hu (2008)



This paper is referenced by
10.3724/SP.J.1008.2012.00095
RGD-modified polylactide-co-glycolic acid tissue engineering scaffolds for bone regeneration: an advance: RGD-modified polylactide-co-glycolic acid tissue engineering scaffolds for bone regeneration: an advance
Chun Tao (2012)
10.1016/J.JDDST.2016.07.004
Albumin coated arginine-capped magnetite nanoparticles as a paclitaxel vehicle: Physicochemical characterizations and in vitro evaluation
Naghmeh Sattarahmady (2016)
10.2147/IJN.S171794
Cyclic RGD-conjugated Pluronic® blending system for active, targeted drug delivery
Chaemin Lim (2018)
Nanotechnology-based Strategies To Enhance Chemo-and Radiation Therapy In Breast Cancer
Preethy Prasad (2014)
10.1016/J.MOLLIQ.2019.02.114
The RGD tripeptide anticancer drug carrier: DFT computations and molecular dynamics simulations
Zahra Nikfar (2019)
10.1073/pnas.1322356111
Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae
J. Voigt (2014)
10.1002/wnan.1406
Modifying the tumor microenvironment using nanoparticle therapeutics.
Aniruddha Roy (2016)
10.1007/978-3-319-11355-5_15
Multifunctional Polymeric Nano-Carriers in Targeted Drug Delivery
A. Agrawal (2015)
10.1155/2017/9090325
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
S. Jahan (2017)
10.1007/s40005-012-0024-5
Recent advances in PLGA particulate systems for drug delivery
Jin-Seok Choi (2012)
10.3390/cancers11060807
The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane
Ki-Hyun Bang (2019)
10.1016/j.jconrel.2020.01.018
Natural IgM dominates in vivo performance of liposomes.
T. Ding (2020)
10.3109/03639045.2012.702348
Preparation, characterization, cellular uptake and evaluation in vivo of solid lipid nanoparticles loaded with cucurbitacin B
H. Hu (2013)
10.1016/j.jconrel.2016.12.024
Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer
Jintian Wu (2017)
10.1515/bnm-2013-0020
Biological targeting with nanoparticles: state of the art
D. Kozlova (2013)
10.1021/bm2010774
Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
P. Lv (2011)
10.1016/J.JDDST.2018.02.007
Gold nanoparticle mediated delivery of fungal asparaginase against cancer cells
G Baskar (2018)
10.1039/C4TB00608A
Insulin-Based Regulation of Glucose-functionalized Nanoparticle Uptake in Muscle Cells.
Yi-Cheun Yeh (2014)
10.1007/978-3-319-08084-0_1
Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Jaydev Upponi (2014)
10.1016/j.ijpharm.2011.03.010
A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
Golam Kibria (2011)
10.1002/adhm.201701035
Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications
Cláudia Martins (2018)
10.1016/j.jconrel.2017.09.026
Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.
Feihu Wang (2017)
10.1038/nrd2591
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros (2010)
10.1021/bm500764p
Integrin-targeted zwitterionic polymeric nanoparticles with acid-induced disassembly property for enhanced drug accumulation and release in tumor.
P. Huang (2014)
10.1186/s11671-015-0864-9
Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent
N. Su (2015)
10.1088/0957-4484/26/36/365104
Poly(D, L-lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and photototoxicity by surface PEG coating.
Ester Boix-Garriga (2015)
10.1016/j.msec.2019.110302
Grand challenges in nanomedicine.
Lin-Ping Wu (2020)
10.1016/j.jconrel.2009.11.012
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.
G. Gaucher (2010)
PROSPECT APPLICATION OF MAGNETO-ENZYMATIC SENSITIVE LIPOSOME FOR IMAGING AND TARGETED RELEASE IN ORAL SQUAMOUS CELL CARCINOMA
Y. Açil (2019)
10.1007/s12010-011-9383-z
Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms
A. Fernandez-Fernandez (2011)
10.1038/s41598-020-71396-x
Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines
Julio M Rios de la Rosa (2020)
10.2147/IJN.S168053
Recent advances in “smart” delivery systems for extended drug release in cancer therapy
Regina-Veronicka Kalaydina (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar